Maintenance Therapy Using Lenalidomide in Myeloma

• Status: Completed
• Trial end date: 2018-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Maintenance treatment of myeloma.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University Hospital, Toulouse
• Collaborators: Celgene; Celgene Corporation; Intergroupe Francophone du Myelome
• Treatments: Lenalidomide; Thalidomide

Criteria

Inclusion Criteria:

• No signs of progression after transplant

• Effective contraception if necessary (oral contraception for females and barrier methods of contraception for sexually active males)

• No active severe infection

• Satisfactory restoration of the haematological parameters defined by: PN >1,000/mm3 and Platelets > 75,000/mm3

• Bilirubin < 35 umol/l and GOT/GPT/PAL<3N

• Creatinine < 160 umol/l.